A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)

oxo Oncology Inc0 个研究点目标入组 250 人开始时间: 2021年9月15日最近更新: 2024年6月3日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 250

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Patients are eligible to be included in the study only if all of the following
•criteria apply:
•1. Age 18 years or older per local regulations at time of enrollment.
•Type of Patient and Disease Characteristics
•2. Confirmed diagnosis by redacted local laboratory report of CLL/SLL as
•defined by iwCLL 2018 criteria including the following:
•a) B-cells co-express CD5 and CD23; express at least one B-cell antigen
•(CD19 or CD20) and be either ? or ? light-chain restricted. Atypical cases
•may be considered with Sponsor approval.
•b) = 5 × 109 B lymphocytes/L (5000/µL) in the peripheral blood for CLL
•patients. For SLL patients, <5 × 109 B cells/L (5000/µL) in the
•peripheral blood is allowed.
•c) Prolymphocytes may comprise = 55% of blood lymphocytes (for CLL
•3. A requirement for therapy consistent with iwCLL 2018 criteria for
•initiation of therapy such that at least 1 of the following should be met:
•a) Evidence of progressive marrow failure as manifested by the
•development of, or worsening of, anemia (such as hemoglobin < 10
•g/dL) and/or thrombocytopenia (such as platelets = 100 × 109/L).
•b) Massive (i.e., spleen edge = 6 cm below the left costal margin) or
•progressive or symptomatic splenomegaly (> 13 cm).
•c) Massive nodes (i.e., = 10 cm in longest diameter) or progressive or
•symptomatic lymphadenopathy.
•d) Progressive lymphocytosis with an increase of > 50% over a 2-month
•period, or lymphocyte doubling time < 6 months. Factors contributing to
•lymphocytosis other than CLL/SLL (e.g., infections, steroid
•administration) should be excluded.
•e) Autoimmune complications including anemia or thrombocytopenia
•poorly responsive to corticosteroids.
•f) Symptomatic or functional extranodal involvement (e.g., skin, kidney,
•lung, spine).
•g) Disease-related symptoms (also known as B-symptoms) as defined by
•any of the following:
•i) Unintentional weight loss = 10% within the previous 6 months.
•ii) Significant fatigue (i.e., Eastern Cooperative Oncology Group [ECOG]
•performance scale 2 or worse; cannot work or unable to perform usual
•activities).
•iii) Fevers = 100.5°F or 38.0°C for 2 or more weeks without evidence of
•iv) Night sweats for = 1 month without evidence of infection.
•4. Eastern Cooperative Oncology Group (ECOG) 0-2.
•5. Must have adequate organ function, as defined below. Results from
•the most recent laboratory tests prior to enrollment will be used for
•eligibility.
•6. Patients are required the have had the following washout periods
•prior to planned C1D1:
•a) Palliative limited field radiation: 7 days
•b) Broad field radiation (= 30% of bone marrow or whole brain
•radiotherapy): 28 days
•Contraception
•7. Willingness women of childbearing potential (WOCBP), and their
•partners, to both observe barrier method and highly effective birth
另有 10 项未显示

排除标准

•Patients are excluded from the study if any of the following criteria apply:
•Medical Conditions
•1. Known or suspected Richter’s transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocytic leukemia, or Hodgkin lymphoma at any time preceding enrollment.
•2. Presence of 17p deletion by fluorescence in-situ hybridization (FISH) (refer to Section 8.10.2)
•3. Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.
•4. Active second malignancy. Patients with treated second malignancy who are in remission with life expectancy > 2 years and with documented Sponsor approval are eligible. Examples include:
•a) Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease.
•b) Adequately treated cervical carcinoma in situ without current evidence of disease.
•c) Localized (e.g., lymph node negative) breast cancer treated with curative intent with no evidence of active disease present for more than 3 years and receiving adjuvant hormonal therapy.
•d) Localized prostate cancer undergoing active surveillance.
•e) History of treated and cured Hodgkin's disease or NHL within 5 years from diagnosis.
•5. Major surgery, within 4 weeks of planned start of study treatment.
•6. A significant history of renal, neurologic, psychiatric, endocrine, metabolic or immunologic, that, in the opinion of the Investigator, would adversely affect the patient’s participation in this study or interpretation of study outcomes.
•7. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) not on a stable regimen and dose for at least 4 weeks prior to study enrollment
•8. Significant cardiovascular disease defined as any of the following:
•a) Unstable angina or acute coronary syndrome within the past 2 months,
•b) History of myocardial infarction within 3 months prior to planned start of study drug,
•c) Documented LVEF by any method of = 40%
•d) = Grade 3 NYHA functional classification system of heart failure, uncontrolled or symptomatic arrhythmias
•9. Prolongation of the QT interval corrected (QTc) for heart rate using Fredericia’s Formula (QTcF) > 470 msec on at least 2 of 3 consecutive ECGs, and mean QTcF > 470 msec on all
•3 ECGs, during Screening.
•a) QTcF is calculated using Fredericia’s Formula (QTcF = QT/(RR^0.33)
•b) Correction of suspected drug-induced QTcF prolongation or prolongation due to electrolyte abnormalities can be attempted at the Investigator’s discretion, and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation or electrolyte supplementation.
•c) Correction of QTc for underlying bundle branch block (BBB) permissible.
•10. Hepatitis B or hepatitis C testing indicating active/ongoing infection based on Screening laboratory tests as defined as:
•a) Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before randomization. Patients who are hepatitis B PCR positive will be excluded.
•b) Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before randomization. Patients who are hepatitis C RNA positive will be exc

研究者

发起方

oxo Oncology Inc

相似试验

进行中（未招募）

1 期

A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/S

EUCTR2021-003206-41-PToxo Oncology, Inc.650

招募中

3 期

A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

JPRN-jRCT2041210150Safi Shahda12

进行中（未招募）

1 期

A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104

CTIS2023-507699-38-00oxo Oncology Inc.650

进行中（未招募）

1 期

A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864

EUCTR2021-001234-20-AToxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company250

进行中（未招募）

1 期

EUCTR2021-001234-20-ESoxo Oncology Inc250